Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe | Nasdaq
ADAPTING
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotechnology
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Neratinib Chapter
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc.
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
